Shandong Xinhua Pharmaceutical Company Limited

DB:XIN Stock Report

Market Cap: €1.2b

Shandong Xinhua Pharmaceutical Management

Management criteria checks 3/4

Shandong Xinhua Pharmaceutical's CEO is Wenhui Xu, appointed in Sep 2022, has a tenure of 2.25 years. total yearly compensation is CN¥1.52M, comprised of 93.8% salary and 6.2% bonuses, including company stock and options. directly owns 0.035% of the company’s shares, worth €421.57K. The average tenure of the management team and the board of directors is 5 years and 4 years respectively.

Key information

Wenhui Xu

Chief executive officer

CN¥1.5m

Total compensation

CEO salary percentage93.8%
CEO tenure2.3yrs
CEO ownership0.04%
Management average tenure5yrs
Board average tenure4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Wenhui Xu's remuneration changed compared to Shandong Xinhua Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

CN¥449m

Jun 30 2024n/an/a

CN¥492m

Mar 31 2024n/an/a

CN¥487m

Dec 31 2023CN¥2mCN¥1m

CN¥497m

Sep 30 2023n/an/a

CN¥510m

Jun 30 2023n/an/a

CN¥486m

Mar 31 2023n/an/a

CN¥454m

Jan 01 2023n/an/a

CN¥411m

Sep 30 2022n/an/a

CN¥357m

Jun 30 2022n/an/a

CN¥343m

Mar 31 2022n/an/a

CN¥357m

Dec 31 2021CN¥1mn/a

CN¥349m

Sep 30 2021n/an/a

CN¥364m

Jun 30 2021n/an/a

CN¥353m

Mar 31 2021n/an/a

CN¥339m

Dec 31 2020CN¥829kn/a

CN¥325m

Compensation vs Market: Wenhui's total compensation ($USD208.52K) is below average for companies of similar size in the German market ($USD1.58M).

Compensation vs Earnings: Wenhui's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


CEO

Wenhui Xu (47 yo)

2.3yrs

Tenure

CN¥1,521,382

Compensation

Mr. Wenhui Xu serves as Executive Director and General Manager of Shandong Xinhua Pharmaceutical Company Limited since October 27, 2022 and September 19, 2022 respectively. He served as the Deputy General...


Leadership Team

NamePositionTenureCompensationOwnership
Tongqing He
Chairman & Deputy GM4yrsCN¥1.61m0.043%
€ 508.6k
Wenhui Xu
GM & Executive Director2.3yrsCN¥1.52m0.035%
€ 421.6k
Ning Hou
CFO, Financial Controller & Executive Director10.7yrsCN¥1.28m0.048%
€ 572.8k
Zhonghui Zheng
Deputy General Manager7.8yrsCN¥1.41m0.043%
€ 508.6k
Changsheng Wei
Deputy GM & Manager of Administrative Personnel Departmentno dataCN¥1.41m0.035%
€ 421.6k
Xuesong Liu
Deputy General Manager2.3yrsCN¥831.80k0.013%
€ 158.7k
Changqiu Cao
Company Secretary27.4yrsCN¥446.80k0.029%
€ 350.5k
Zuxing Kou
Deputy General Manager2.3yrsCN¥1.10m0.011%
€ 129.1k
Haifeng Guo
Head of Accounting Departmentno datano datano data
Xiaohong He
Chief of Finance Departmentno datano datano data

5.0yrs

Average Tenure

51yo

Average Age

Experienced Management: XIN's management team is seasoned and experienced (5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Tongqing He
Chairman & Deputy GM4yrsCN¥1.61m0.043%
€ 508.6k
Wenhui Xu
GM & Executive Director2.2yrsCN¥1.52m0.035%
€ 421.6k
Ning Hou
CFO, Financial Controller & Executive Director2.2yrsCN¥1.28m0.048%
€ 572.8k
Zhichao Tao
Independent Supervisor22.5yrsCN¥24.00kno data
Lie Xu
Non-Executive Director14.5yrsCN¥1.41m0.043%
€ 508.6k
Yanhua Hu
Employee Supervisor13.4yrsCN¥181.00kno data
Guangcheng Pan
Independent Non-Executive Director4yrsCN¥100.00kno data
Chengtong Liu
Chairman of Supervisory Committee4yrsno datano data
Jianwei Zhu
Independent Non-Executive Director4yrsCN¥100.00kno data
Peixue Ling
Independent Non-Executive Director2.2yrsCN¥58.33kno data
Chengyong Zhang
Non-Independent Directorless than a yearno datano data
Ching Ching Cheung
Independent Non-Executive Directorless than a yearno datano data

4.0yrs

Average Tenure

54yo

Average Age

Experienced Board: XIN's board of directors are considered experienced (4 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:26
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shandong Xinhua Pharmaceutical Company Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alex FanGF Securities (Hong Kong) Brokerage Limited
Ming LiIndustrial Securities Co. Ltd.
Guohe FanPhillip Securities (HK)